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There is an unmet need for markers that can stratify different forms and subtypes of dementia. Because
of similarities in clinical presentation, it can be difﬁcult to distinguish between Alzheimer’s disease (AD)
and frontotemporal dementia (FTD). Using a multiplex targeted proteomic LC-MS/MS platform, we
aimed to identify cerebrospinal ﬂuid proteins differentially expressed between patients with AD and FTD.
Furthermore analysis of 2 conﬁrmed FTD genetic subtypes carrying progranulin (GRN) and chromosome
9 open reading frame 72 (C9orf72) mutations was performed to give an insight into the differing pa-
thologies of these forms of FTD. Patients with AD (n ¼ 13) demonstrated a signiﬁcant (p < 0.007) 1.24-
fold increase in pro-orexin compared to FTD (n ¼ 32). Amyloid beta-38 levels in patients with AD were
unaltered but demonstrated a >2-fold reduction (p < 0.0001) in the FTD group compared to controls and
a similar 1.83-fold reduction compared to the AD group (p < 0.001). Soluble TREM2 was elevated in both
dementia groups but did not show any difference between AD and FTD. A further analysis comparing FTD
subgroups revealed slightly lower levels of proteins apolipoprotein E, CD166, osteopontin, transthyretin,
and cystatin C in the GRN group (n ¼ 9) compared to the C9orf72 group (n ¼ 7). These proteins imply GRN
FTD elicits an altered inﬂammatory response to C9orf72 FTD.
 2018 Published by Elsevier Inc.1. Introduction
It is estimated that over 850,000 people live with dementia in
the UK alone and this ﬁgure is predicted to rise to over 2 million in
the next 50 years. Research into new therapies and development of
new drugs to stop or slow the progression of neurodegeneration is
thus a major priority in health care. Development of treatment has
been confounded in the past by difﬁculties in identifying the correct
patients for new drug trials as it can be difﬁcult clinically to
distinguish between some forms as dementia such as Alzheimer’s
disease (AD) and frontotemporal dementia (FTD). Differential
diagnosis between AD and FTD may be challenging as AD mayl Omics, UCL Great Ormond
(0)2079052873; fax: þ44 (0)
Elsevier Inc.manifest with behavioral disturbances (the “frontal variant”
(Dubois et al., 2014)) whereas, on the other side, memory distur-
bances may manifest in FTD, particularly in carriers of GRN and
chromosome 9 open reading frame (C9orf72)mutations (Galimberti
et al., 2015; Pietroboni et al., 2011). Cerebrospinal ﬂuid (CSF) bio-
markers amyloid beta 1-42 (Ab), total tau (tau), and Tau phos-
phorylated at position 181 (Ptau) have a good accuracy in predicting
AD (Mulder et al., 2010). In clinical practice, this analysis helps to
rule out AD, but apparently normal results cannot exclude FTD, as
no speciﬁc biomarkers are available for this disease. Moreover, tau
may be altered in FTD (as well as in many other neurodegenerative
conditions), but surprisingly values are often normal in genetic
forms, despite evidence of clinical deterioration (Carecchio et al.,
2011). It is also possible that the CSF total- and phospho-tau (t-
tau and p-tau, respectively) increase in AD is not a direct effect of
tau pathology and neurodegeneration but rather reﬂects increased
tau secretion from AD-affected neurons, as suggested in both
W.E. Heywood et al. / Neurobiology of Aging 72 (2018) 171e176172animal studies (Maia et al., 2013) and a recent tau kinetics study in
man (Sato et al., 2018). Further biomarkers are still needed as there
is growing consensus that multiple biomarker panels may be the
way forward in discriminating a molecular signature for individual
dementias and their subtypes (Carecchio et al., 2011; Mulder et al.,
2010). Targeted proteomics using multiple reaction monitoring
liquid chromatography tandem mass spectrometry (MRM LC-MS/
MS) is a useful technique in streamlining biomarker development.
It does not require antibodies and can assay multiple proteins in a
sample. Once a method is developed, it is capable of performing
high-throughput analysis of multiple samples thereby enabling
assessment of candidate markers. We have applied a previously
described targeted proteomics platform of multiple markers of
neurodegeneration in CSF from patients (Heslegrave et al., 2016a;
Heywood et al., 2015; Paterson et al., 2016). We describe the use
of this assay to analyze multiple biomarkers of neurodegeneration
in the CSF from patients with AD, sporadic FTD, and 2 forms of
genetic FTD (patients with mutations in GRN or C9orf72). We have
looked for proteins that show a change between the 2 different
dementias AD and FTD and also an analysis looking at proteins that
show changes between sporadic and genetic subtypes of FTD.
Looking at the differences between the different FTD groups will
hopefully give an insight into the potential molecular pathology of
these forms of FTD.2. Methods
2.1. Ethics approval and consent to participate
Informed consent to participate in this study was given by all
subjects or their caregivers. All samples were obtained from the
Neurodegenerative Disease Unit of the Fondazione Cà Granda,
IRCCS Ospedale Maggiore Policlinico, University of Milan (Milan,
Italy).2.2. CSF sample criteria, collection, and routine analysis
Sample data is given in Table 1. Patients were recruited
consecutively at the Neurodegenerative Disease Center of the
Ospedale Policlinico between 2013 and 2015. The clinical workup
included medical history, physical and neurological examination,
screening laboratory tests, neurocognitive evaluation, lumbar
puncture for Ab, tau, and Ptau evaluation, and imaging. Cognitive
functions were assessed by the clinical dementia rating (CDR), the
mini mental state examination (MMSE), the frontal assessment
battery (FAB), the Wisconsin Card Sorting Test (WCST), and the
Tower of London test. The presence of signiﬁcant vascular brain
damagewas excluded (Hachinski Ischemic Score<4). The diagnosis
of FTDwas made according to consensus criteria (Neary et al., 1998)
and subsequent revisions (McKhann et al., 2001; Rascovsky et al.,
2011).Table 1
Characteristics of AD patients, FTD patients, and controls
Subject details Controls (n ¼ 15) AD patients (n ¼ 13)
Gender (M/F) 5:10 5:8
Age, years (mean  SD) 61.0  9.9 72.1  6.8
APOE ε4 positive (%) 13.3% 69.2%
CSF Biomarkers
Ab1-42 (pg/mL), median (IQR) 895 (794e1132) 446 (331.2e498.5)
T-tau (pg/mL), median (IQR) 91  (59-155) 481 (264e666)
P-tau (pg/mL), median (IQR) 20.5 (17e28) 84 (56e105)
Data expressed as mean  SD or median (IQR) as appropriate.Patients with AD (n ¼ 13) all had abnormal CSF Ab, t-tau, and p-
tau levels, thus conﬁrming the clinical diagnosis (G. McKhann et al.,
1984) with an accuracy of about 90 % (Table 1), in accordance with
more recent criteria (Dubois et al., 2010) (Dubois et al., 2007).
Thirty-two patients with FTD were included: 7 GRN mutation car-
riers, 9 C9orf72 expansion carriers, and 16 with sporadic disease.
Controls (n ¼ 15) included patients undergone lumbar puncture
on suspicion of neurological diseases that were disclosed with no
evidence of neurological deﬁcits and cognitive impairment. This
cohort has previously been investigated for the effect of age on the
proteins described in this study (Heywood et al., 2015). Only
markers that did not show any signiﬁcant change with age are
presented in this study.
Clinical CSF was sampled according to a standard protocol
(Blennow et al., 2010). CSF samples were obtained in polypropylene
tubes by LP at the L4/L5 or L3/L4 interspace, centrifuged at 4 C, and
stored at 30 C until analysis. CSF cell counts, glucose, and
proteins were determined. Routine analysis to exclude damage of
the blood-brain barrier (BBB) included measurement of albumin by
rate nephelometry and the intrathecal IgG production. The albumin
quotient (CSF albumin/serum albumin) X 103 and the IgG index (CSF
albumin/serum albumin)/(CSF IgG/serum IgG) were calculated and
samples without BBB damage were used in the study, which
conﬁrm that the proteins measured in this study are produced
intrathecally and not leaking from the periphery (Sellebjerg and
Christiansen, 1996).2.3. Ab, tau, and Ptau measurement
CSF tau concentration was determined using a sandwich
enzyme-linked immunosorbent assay (ELISA) (INNOTEST hTAU-Ag,
Fujirebio, Ghent, Belgium) speciﬁcally constructed to measure all
tau isoforms irrespective of phosphorylation status. CSF Ptau was
measured using a sandwich ELISA speciﬁcally detecting tau phos-
phorylated at amino acid 181 (INNOTEST PHOSPHO-TAU (181P),
Fujirebio, Ghent, Belgium). Ab levels were determined using a
sandwich ELISA (INNOTEST ß- AMYLOID Fujirebio, Ghent, Belgium).
Normal values of biomarkers were as follows: Ab->550 pg/mL; tau
< 375 pg/mL; and Ptau < 52 pg/mL (Mulder et al., 2010).2.4. Targeted proteomics: MRM-based triple quadrupole mass
spectral assay
A 54-protein MRM LC-MS/MS multiplex assay was originally
designed to quantitate altered proteins that were identiﬁed from
proteomic proﬁling of CSF from dementia patients as well as
biomarker candidates suggested in the current literature at that
time. Further detailed information regarding the selection and
method development of the assay can be found in (Heywood et al.,
2015). The initial analyses in this study were performed to identify
proteins speciﬁc to the dementia type. Therefore, the FTD group
comparison consisted of the GRN, C9orf72 mutation carriers, andSporadic FTD (n ¼ 16) C9orf72 FTD (n ¼ 7) GRN FTD (n ¼ 9)
10:6 6:1 3:6
71.8  7.3 66.0  8.0 63.5  8.5
56.2% 14.2% 22%
656 (552.3e741.8) 839 (692e1141) 841 (687e1314)
688 (173e1114) 291 (239e367) 328 (268e440)
72 (28e107) 68 (38e84) 27(17e33)
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enolase protein standard (Sigma, UK) and 10e50 pmols heavy
labeled peptide standards (Thermo Scientiﬁc, UK) were added to
100 mL of CSF. CSF was freeze-dried and trypsin-digested as
described previously (Heywood et al., 2012). A single 35 mL injection
of each CSF digest was injected onto a Waters CORTECS UPLC
C18þColumn, 90 Å, 1.6 mm, 3 mm  100 mm column attached to a
C18þ VanGuard precolumn. UPLC and MS tune conditions were
performed as described previously (Manwaring et al., 2013). QC
runs of pooled CSF digests were run in triplicate at the start of the
run and then every 10 injections. A CV within15% for each QC was
considered acceptable. Chromatograms were analyzed using Wa-
ters Targetlynx software. Peptides were standardized by either
using a spiked heavy labeled peptide or to a yeast enolase peptide.
Absolute levels of pmols/100 mL CSF were obtained from standard
curves.2.5. Statistical analysis
Analyses included data QC for peptide performance (coefﬁcient
of variance), QC of sample preparation, and LC-MS/MS performance
(yeast enolase). The normality of the variables was evaluated using
D’Agostino-Pearson’s test. Non-normally distributed variables were
transformed to Gaussian distribution by the operations listed in
Supplementary Data 2. The differences in protein expression be-
tween the groups were evaluated using one-factor ANOVA in
conjunction with Tukey’s multiple comparison post-test or Mann-
Whitney U nonparametric test. Group age ranges were checked
for signiﬁcant difference using a Kruskal-Wallis with Dunns post-
test of which no signiﬁcant difference was conﬁrmed.3. Results
3.1. Dementia grouped analysis
Only 2 proteins showed signiﬁcant changes when samples were
grouped according to dementia type (Fig. 1). Ab-38 demonstrated a
slight but not signiﬁcant reduction in the mean of the AD group.
However, the FTD group demonstrated a much greater and signif-
icant 2.6-fold reduction compared with controls (p < 0.0001) and a
signiﬁcant 1.83-fold reduction compared to the AD group (p <
0.001). Pro-orexin levels were statistically and signiﬁcantly
increased in both dementia groups with a 1.5-fold increase in FTD
compared to controls (p < 0.001) and a 1.87-fold increase in the AD
group (p < 0.0001). The AD group also demonstrated a signiﬁcant
1.24-fold higher level of pro-orexin when compared to the FTD
group (p < 0.01). Soluble TREM2 (sTREM2) was included in the
analysis and has previously been demonstrated to be elevated in ADFig. 1. Proteins differently expressed between AD and FTD. (A) a-beta-38 (untransformed d
elevated in both AD and FTD but there is no difference between the dementias. * indicates p
Witney U analysis. Key: AD, Alzheimer’s disease; FTD, frontotemporal dementia; sTREM2, susing our assay (Heslegrave et al., 2016b) and been shown to be
elevated previously in FTD CSF by ELISA (Piccio et al., 2016). CSF
levels of sTREM2were signiﬁcantly elevated in both the AD and FTD
groups relative to the control group (p < 0.0006). sTREM2 levels
although elevated in both the AD and FTD groups were not different
between both the neurodegenerative conditions. Correlation anal-
ysis with levels of routinely measured known disease CSF markers
amyloid Ab, tau, and Ptau did not demonstrate any relationship
with pro-orexin or sTREM2 levels in CSF of either dementia. There
was signiﬁcant correlation between levels of Ab-38 with Ptau in AD
(r2 ¼ 0.37 p < 0.028) but not FTD. However, Ab-38 did show a
correlation with Ab-42 in the FTD group (r2 ¼ 0.38, p < 0.001)
(Supplementary Data 1).3.2. FTD subgroup analysis
The FTD group was subdivided into 2 groups consisting of those
patients carrying GRN mutations and those with C9orf72 expan-
sions. Five proteins showed small but signiﬁcant changes (p <
0.04e0.01) between the GRN and C9orf72 groups. The proteins in
the GRN group which consistently showed a lower level relative to
the C9orf72 group were apolipoprotein E, CD166, transthyretin,
osteopontin, and cystatin C (Fig. 2).4. Discussion
In previous work by our laboratory, we demonstrated that our
method revealed signiﬁcantly elevated proteins in the CSF of pa-
tients with AD relative to controls. Therefore, the aim of this study
was to determine if our test was capable of detecting proteins
altered between AD and FTD and if it was possible to see changes
between FTD carrying different causal mutations. We found that
only 2 proteins (pro-orexin and Ab-38) differed in expression be-
tween the AD and FTD groups, whereas 5 proteins were altered
between carriers of different mutations in FTD.
Analysis of pro-orexin levels revealed that this protein was
slightly signiﬁcantly elevated in AD compared to patients with FTD.
Pro-orexin has been implicated previously in the pathogenesis of
AD (Liguori et al., 2014; Malkki, 2014) and in particular the hypo-
thalamic dysfunction related to sleep impairment in AD (Liguori
et al., 2017). Sleep disturbance can also be observed in FTD albeit
not as commonly (McCarter et al., 2016). Consistent with this, we
observed raised CSF pro-orexin in FTD compared with controls but
to a lesser extent than AD (Coban et al., 2013). It would be useful in
future studies to correlate the presence of sleep symptoms with
pro-orexin levels to see whether abnormalities in this protein can
predict the presence of sleep disturbance.ata) and (B) pro-orexin are signiﬁcantly altered between FTD from AD. (C) sTREM2 is
< 0.05, **p < 0.01***, p < 0.001, ****p < 0.0001 as determined by nonparametric Mann-
oluble TREM2.
Fig. 2. Proteins altered between the C9orf72 and GRN genetic forms of FTD. * indicates p < 0.05, ** p < 0.01 as determined by nonparametric Mann-Witney U analysis. Key: FTD,
frontotemporal dementia.
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conﬁrms previous observations by other groups (Bibl et al., 2011;
Gabelle et al., 2011). However, the reason for this remains unclear.
Although AD pathology can occasionally be seen as an additional
ﬁnding at postmortem in patients with FTD, amyloid has not been
implicated more generally in the pathophysiology of the FTD syn-
dromes and Ab-38 is not a plaque-associated form of Ab. The levels
of Ab-42 and Ab-40 overall are not altered to the degree as that seen
for Ab-38 in the FTD group. This indicates the effect on Ab-38 is
downstream of this mechanism and likely due to increased prote-
olysis. Ab-38 can be cleaved by other enzymes such as neprilysin,
insulin-degrading enzyme, endothelin-converting enzyme,
angiotensin-converting enzyme, and the plasmin/uPA/tPA (Wang
et al., 2006), and potentially, Ab-38 is a better substrate for these
proteases than the other Ab peptides. Interestingly, some other
substrates of these proteases particularly neprilysin are feeding
hormones. Alterations in feeding behavior are a known clinical
feature in some forms of FTD (Woollacott and Rohrer, 2016). It is
possible that dysregulation of such a protease could be an initiating
factor for some of the downstream pathological features in FTD.
Neprilysin has been studied in the context of AD more for its po-
tential as a plaque treatment (Meilandt et al., 2009) but so far
neprilysin has not been investigated in FTD. Another theoretical
explanation for the more pronounced decrease of Ab-38 in FTD
could be g-secretase modulation; decreased processivity of APP by
g-secretase could result in lower concentrations of shorter Ab
peptides, such as Ab38 (Chavez-Gutierrez et al., 2012), but this has
to the best of our knowledge not been studied in FTD. We did
attempt to look at proteins that could be altered just in sporadic FTD
but no speciﬁc changes were observed apart from the previous pro-
orexin and amyloid beta 38. Because of the heterogeneity of FTD
pathology, this is unsurprising. Until further understanding of
sporadic FTD at a molecular level is understood, it is hard to identify
proteins that indicate speciﬁc subpathologies.
When subgrouping the FTD patients by genetic status, 5 proteins
measured in the multiplex assay demonstrated a small but signif-
icant difference between the 2 genetic FTD groups, with lowerlevels in the GRN group compared with C9orf72 group. Reduced
expression of cystatin C has been described in response to systemic
inﬂammation in dendritic cells (Xu et al., 2011). This is consistent
with previous work suggesting differential involvement of inﬂam-
matory pathways in GRN-related FTD compared with other sub-
types of FTD (Martens et al., 2012). However, the other proteins
(osteopontin, CD166, transthyretin, apolipoprotein E) have also
been postulated to be involved in the inﬂammatory response
(Bowen and Aruffo, 1999; Rebeck, 2017; Shin, 2012) but this does
not corroborate with GRN neuropathology which is found to be
more profound than that observed in C9orf72 pathology. One
reasoning for this observation could be that these proteins maybe
reduced in GRN CSF due to being sequestered at sites of inﬂam-
mation in the brain. Further work should aim to replicate these
measures in a larger FTD data set and understand further their exact
role in FTD.
This study shows that a targeted MRM platform measuring
multiple proteins are able to not only help to ﬁnd proteins with
altered expression between AD from FTD but can also identify
differential involvement of proteins in FTD subtypes, consistent
with the different pathophysiological mechanisms underlying
these different forms of dementia. Limitations of this study include
(1) the modest number of samples; and (2) the lack of pathological
demonstration of the pathology, particularly in sporadic FTD, for
which no biomarkers exist. As with discovery of all potential bio-
markers, independent validation on separate and much larger co-
horts will be required for any future clinical utilization. We believe
this initial analysis and platform are a valuable proviso toward
achieving this further validation in larger cohorts of clinically well-
deﬁned samples. Another strength of this platform is that other
possible candidate biomarkers suggested from other studies and
even possibly neprilysin from our own ﬁndings could be added to
the panel.
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